Top Markets
Coin of the day
Mural Oncology plc Mural Oncology plc

Mural Oncology plc

MURA
Clasificación en acciones #27064
Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and... Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects centered on modified interleukin-18 and tumor-specific interleukin-12. Incorporated in 2017, Mural Oncology maintains its headquarters in Dublin, Ireland. By November 15, 2023, the company had transitioned from being a subsidiary of Alkermes plc.
Precio por acción
$2.04
Última sincronización: 2025-12-09
Capitalización bursátil
$35.38M
Cambio (1 día)
0.00%
Cambio (1 año)
-2.39%
País
IE
Comercio Mural Oncology plc (MURA)

Categoría

Ganancias de Mural Oncology plc (MURA)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Mural Oncology plc, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Mural Oncology plc desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
$-3.09B -
US
- -
CH